MarketCap
Facebook
X
Telegram
Lixte Biotechnology Holdings EV - Enterprise Value | LIXT
Annual EV - Enterprise Value Lixte Biotechnology Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23.7 M | 6.18 M | 203 K | -4.04 M | 11.2 M | 29.5 M | 47.9 M | 48.9 M | 6.32 M | 5.76 M | 11 M | 7.33 M | 2.76 M | 24.6 M | 17.9 M | 1.05 B | -1.54 M | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.05 B | -4.04 M | 75.9 M |
EV - Enterprise Value of other stocks in the Biotechnology industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Magenta Therapeutics
MGTA
|
-13.6 M | - | -7.74 % | $ 41.6 M |  USA |
 |
NovaBay Pharmaceuticals
NBY
|
640 M | - | - | $ 11.3 M | USA |
 |
NeuroBo Pharmaceuticals
NRBO
|
-4.49 M | - | 0.43 % | $ 12 M | USA |
 |
OncoCyte Corporation
OCX
|
45.6 M | - | 17.22 % | $ 355 K | USA |
 |
Onconova Therapeutics
ONTX
|
7.43 M | - | -0.47 % | $ 21 M | USA |
 |
Opthea Limited
OPT
|
209 M | - | - | $ 1.2 B |  Australia |
 |
Verastem
VSTM
|
388 M | $ 8.55 | -8.85 % | $ 593 M | USA |
 |
BiomX
PHGE
|
4.2 M | $ 1.85 | 14.2 % | $ 3.02 M |  Israel |
 |
Pieris Pharmaceuticals
PIRS
|
-26.4 M | - | -15.58 % | $ 1.22 B |  Germany |
 |
Plus Therapeutics
PSTV
|
30.6 M | - | - | $ 301 M | USA |
 |
Pluristem Therapeutics
PSTI
|
-3.53 M | - | -1.9 % | $ 33.3 M | Israel |
 |
Qualigen Therapeutics
QLGN
|
-19.3 M | - | 5.59 % | $ 1.16 M | USA |
|
Qilian International Holding Group Limited
QLI
|
32.1 M | - | -6.08 % | $ 184 M |  China |
 |
Cassava Sciences
SAVA
|
51.3 M | - | - | $ 110 M | USA |
 |
Selecta Biosciences
SELB
|
298 M | - | -8.69 % | $ 126 M | USA |
 |
Sangamo Therapeutics
SGMO
|
140 M | - | - | $ 50.4 M | USA |
 |
Salarius Pharmaceuticals
SLRX
|
-5.54 M | - | - | $ 2.64 M | USA |
 |
Sensei Biotherapeutics
SNSE
|
27.3 M | - | - | $ 17.5 M | USA |
 |
Sonnet BioTherapeutics Holdings
SONN
|
-1.02 M | - | - | $ 826 K | USA |
 |
Synthetic Biologics
SYN
|
9.8 M | - | 1.32 % | $ 16.2 M | USA |
 |
Synlogic
SYBX
|
-14.7 M | - | - | $ 7.07 M | USA |
 |
Virios Therapeutics, LLC
VIRI
|
8.75 M | - | 2710.01 % | $ 72.9 M | USA |
 |
Vallon Pharmaceuticals
VLON
|
-5.57 M | - | -6.47 % | $ 5.76 M | USA |
 |
Vaxart
VXRT
|
187 M | - | -25.06 % | $ 46.3 M | USA |
 |
XOMA Corporation
XOMA
|
416 M | - | - | $ 485 M | USA |
 |
Repare Therapeutics
RPTX
|
-9.3 M | - | - | $ 112 M |  Canada |
 |
Sesen Bio
SESN
|
66.6 M | - | 7.29 % | $ 127 M | USA |
|
Windtree Therapeutics
WINT
|
81.3 M | - | - | $ 26.8 M | USA |
 |
Trean Insurance Group
TIG
|
1.47 B | - | - | $ 316 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
-3.96 M | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
-4.64 M | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
-5.65 M | - | - | $ 13 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
14.1 M | - | - | - |  Russia |
 |
Lyra Therapeutics
LYRA
|
30.9 M | - | - | $ 24.9 M | USA |
 |
Brickell Biotech
BBI
|
515 K | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
-49.7 M | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
-26.7 M | - | - | $ 8.86 M | Canada |
 |
Generation Bio Co.
GBIO
|
68.7 M | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
44 M | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
2.82 B | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
-72 M | - | - | $ 2.36 B | USA |
 |
Annexon
ANNX
|
673 M | $ 4.21 | 4.99 % | $ 653 M | USA |
 |
AbbVie
ABBV
|
394 B | $ 291.22 | 1.06 % | $ 515 B | USA |
 |
22nd Century Group
XXII
|
1.92 M | $ 1.56 | -19.17 % | $ 287 K | USA |
 |
Axon Enterprise
AXON
|
33.2 B | $ 313.68 | -18.01 % | $ 24.5 B | USA |
 |
Biogen
BIIB
|
37.6 B | $ 248.51 | 1.88 % | $ 36.4 B | USA |